Chemomab Therapeutics (CMMB) Shares Outstanding (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Shares Outstanding data on file, last reported at $575.4 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding rose 52.57% year-over-year to $575.4 million; the trailing twelve-month figure through Dec 2025 stood at $575.4 million (up 52.57% YoY), and the FY2025 full-year result was $575.4 million, up 52.57% from the prior year.
• Shares Outstanding for Q4 2025 stood at $575.4 million, up from $377.1 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $575.4 million in Q4 2025 and bottomed at $214.0 million in Q1 2021.
• The 5-year median for Shares Outstanding is $228.8 million (2022), against an average of $273.8 million.
• The widest annual swing landed in 2021, when Shares Outstanding surged 2357.79%; it then tumbled 105.1% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $228.0 million in 2021, then advanced by 2.05% to $232.6 million in 2022, then rose by 22.12% to $284.1 million in 2023, then surged by 32.75% to $377.1 million in 2024, then surged by 52.57% to $575.4 million in 2025.
• The last three Shares Outstanding figures came in at $575.4 million (Q4 2025), $377.1 million (Q4 2024), and $284.1 million (Q4 2023), per Business Quant data.

Peer Comparison